Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12606000303549
Ethics application status
Not required
Date submitted
28/06/2006
Date registered
14/07/2006
Date last updated
18/06/2021
Date data sharing statement initially provided
18/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of engraftment kinetics following double unit umbilical cord blood transplantation in patients with life threatening haematological malignancy in whom stem cell transplant (SCT) offers the only prospect of cure.
Scientific title
Evaluation of engraftment kinetics following double unit umbilical cord blood transplantation in patients with life threatening haematological malignancy in whom stem cell transplant (SCT) offers the only prospect of cure.
Secondary ID [1] 280 0
Australasian Leukaemia and Lymphoma Group (ALLG): ALLG BM08
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
High risk haematological malignancy 1276 0
Condition category
Condition code
Blood 1363 1363 0 0
Haematological diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Double Unit Cord Blood Transplantation in patients with high risk haematological malignancy in whom SCT offers the only prospect of cure.
Intervention code [1] 1177 0
Treatment: Other
Comparator / control treatment
No comparator.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 1857 0
To estimate the time to neutrophil and platelet engraftment of double unit unrelated cord blood transplantation in adult patients with high risk malignancy. Specifically, to analyse the ability of a two unit cord blood transplant with Filgrastim support to achieve timely engraftment.
Timepoint [1] 1857 0
Donor chimerism at days 28, 56, 100, 180, 270 and 365 will be reported for each of these time points in the form of summary statistics
Secondary outcome [1] 3275 0
To assess chimerism
Timepoint [1] 3275 0
Chimerism will be measured at days 30, 60, 90, 180, 360, 540 and 730 post-transplantation.
Secondary outcome [2] 3276 0
Graft vs host disease (GVHD)
Timepoint [2] 3276 0
GVHD will be measured at the dates of diagnosis, histopathology and therapy with response and then on days 100, 180, 365.
Secondary outcome [3] 3277 0
Toxicity and safety
Timepoint [3] 3277 0
Toxicity and safety will be measured as clinically indicated.
Secondary outcome [4] 3278 0
Disease free survival (DFS) and overall survival (OS)
Timepoint [4] 3278 0
Disease free survival and overall survival will be measured at days 28, 100, 180, 365, 730 and other timepoints as clinically indicated.

Eligibility
Key inclusion criteria
1. H\Patients with high risk haematological malignancy in whom stem cell transplant offers the only prospect of cure, but do not have either a fully matched or one-antigen mismatched related donor or an identified suitable matched unrelated donor (URD).2. ECOG performance status 0-2. 3. Satisfactory major organ function- Cardiac function as measured by either a gated blood pool scan or echocardiogram showing left ventricular ejection fraction > 40%.- Pulmonary function as measured by a DLCO ³ 50% of normal.- Renal function as measured by a calculated or actual creatinine clearance > 30 ml/min.- Hepatic function as measured by a serum bilirubin greater than or equal to 30 micromol/l and transaminases greater than or equal to 2 x ULN. 4. Absence of severe uncontrolled infection. 5. Written informed consent given by recipient.
Minimum age
Not stated
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients with a suitable matched related or unrelated donor in whom marrow or peripheral blood stem cells can be procured within a satisfactory time period.2. Patients who are positive for hepatitis B, hepatitis C or HIV.3. Pregnant or lactating women.4. No contraindication to use of any of the study drugs, including known sensitivity to E coli derived preparations.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Withdrawn
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
subject to verification
Date of first participant enrolment
Anticipated
1/09/2006
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 1497 0
Commercial sector/Industry
Name [1] 1497 0
Amgen Australia
Country [1] 1497 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Leukaemia and Lymphoma Group
Address
35 Elizabeth St, Richmond VIC 3121
Country
Australia
Secondary sponsor category [1] 1315 0
None
Name [1] 1315 0
nil
Address [1] 1315 0
Country [1] 1315 0

Ethics approval
Ethics application status
Not required

Summary
Brief summary
The use of umbilical cord blood (CB) as a source of haemopoietic stem cells (HSC) for transplantation is increasing. Advantages of using CB compared to other sources of HSC include a reduction in search time and procurement, a low risk of transmission of viral disease and a reduced incidence of graft versus host disease. Delayed engraftment, due to the low cell number in CB grafts, has emerged as the limiting factor to more widespread use of CB as a source of HSC. Transplantation of multiple CB units is one approach to overcome low cell numbers and preliminary results are encouraging. In this study, patients with high risk haematological malignancy who require a HSC transplant but do not have a related or unrelated donor will receive a double unit CB transplant. The study hypothesis is that transplantation of two cord blood units is feasible and safe to administer.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35591 0
Dr Dr Ian D Lewis
Address 35591 0
Division of Haematology
Institute of Medical and Veterinary Science
Frome Road, Adelaide, SA 5000
Ph: 08-8222 3328; Fax: 08-8222 3162
E-Mail: [email protected]
Country 35591 0
Australia
Phone 35591 0
+61 0882223328
Fax 35591 0
+61 08-8222 3162
Email 35591 0
[email protected]
Contact person for public queries
Name 10366 0
Dr Dr Ian Lewis
Address 10366 0
Haematology/Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000
Country 10366 0
Australia
Phone 10366 0
08-8222 3328
Fax 10366 0
08-8222 3328
Email 10366 0
[email protected]
Contact person for scientific queries
Name 1294 0
Dr Dr Ian Lewis
Address 1294 0
Haematology/Oncology Royal Adelaide Hospital North Terrace Adelaide SA 5000
Country 1294 0
Australia
Phone 1294 0
08-8222 3328
Fax 1294 0
08-8222 3328
Email 1294 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
12129Study protocol    1432-(Uploaded-01-12-2020-13-04-20)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.